Clinical trials
Pediatric Solid Tumor clinical trials
Below are recruiting pediatric solid tumor clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02315599Enrolling by invitation
Follow-up for delayed side effects after gene-cell therapy
This study checks people for delayed side effects after receiving gene-based cell therapy from the NIH. It helps doctors learn what problems may happen later and how to monitor them safely.
Bethesda, MarylandAges 1–99 - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39 - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT03838042RecruitingPhase 1/Phase 2
Testing nivolumab plus entinostat for high-risk childhood cancers
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Randwick, New South WalesAges 2–21 - NCT03988283RecruitingPhase 1
Personalized DNA vaccine for recurrent childhood brain tumors
This trial tests a personalized DNA vaccine made from your tumor’s DNA (neoantigens) to help your immune system fight the cancer. It is designed for children and young adults with certain recurrent or newly diagnosed brain/spine tumors, after they have had other standard treatments and tumor tissue is available for testing.
St Louis, MissouriAges Up to 25 years - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Iowa City, IowaAges 1 month–17 years - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years - NCT07755826Recruiting
Repotrectinib safety study in Japanese children with NTRK fusion tumors
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Minato-ku, TokyoAges 4–17 - NCT05120518Recruiting
Donate a child’s tumor tissue for research after passing
This study collects a child’s tumor tissue and cells after death to help researchers learn more about cancers and other tumor conditions. You can take part if the required consent and permission are completed.
Chicago, IllinoisAges Any age - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT06208657RecruitingPhase 1/Phase 2
Personalized cancer therapy for kids and teens
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
Newcastle, New South WalesAges birth–21 years - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT02530658Recruiting
Sequencing children’s tumor and normal tissue samples
This study collects children’s normal and tumor tissue (or blood-related normal samples) and reads their DNA/RNA to look at genetic information. It may help researchers understand cancer-related changes and improve future testing, even when the goal isn’t to treat you directly.
Memphis, TennesseeAges Any age - NCT00571389Recruiting
Collecting blood cells from people with cancer or COVID-19
This study collects blood cells using a special blood-draw procedure called leukapheresis (for some participants) and other samples. It aims to better understand cancer and immune-related cells, which may help researchers design or improve future treatments.
Huntersville, North CarolinaAges 5 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT05918640RecruitingPhase 1/Phase 2
Lurbinectedin for cancers with specific EWS-related gene fusions
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
Los Angeles, CaliforniaAges 10 years+ - NCT04764357Recruiting
Scalp cooling to help prevent chemotherapy-related hair loss in kids
This study looks at whether “cold cap” scalp cooling can help prevent or reduce hair loss in children getting chemotherapy. It’s aimed at kids treated with certain chemotherapy medicines and who may be at risk for losing their hair.
Memphis, TennesseeAges 7 years+ - NCT06579469Recruiting
Study of later effects of CAR T cell therapy
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
Aurora, ColoradoAges Up to 30 years - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Mesa, ArizonaAges Any age - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Beverly Hills, CaliforniaAges 8 years+
Hear when a new Pediatric Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pediatric solid tumor?
- Yes. Clin2 currently lists 79 recruiting pediatric solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pediatric solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pediatric solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.